Non-classical HLA-G antigen and its role in the cancer progression
- PMID: 16537188
- DOI: 10.1080/07357900500524579
Non-classical HLA-G antigen and its role in the cancer progression
Abstract
Various changes take place during the progression of cancer, some of which are favorable for tumor development and may help to escape the immunosurvillance. These include changes in the microenvironment around the developing tumor, which could be produced in response to phenotypic alterations or could modulate the expression of certain markers of tumor development. One such newly discovered molecule is HLA-G, which has been found to have immunosuppressive and immunomodulatory roles in the cancer development. The regulatory sequences, as seen, may be induced by various factors that may be present in tumor microenvironment. A recent study has investigated the antigen -G as a marker of susceptibility to chemotherapy. Further, its expression on tumors and how it can be exploited for diagnosis and therapy is discussed in this article.
Similar articles
-
HLA-G expression in malignant melanoma.Semin Cancer Biol. 2007 Dec;17(6):422-9. doi: 10.1016/j.semcancer.2007.06.010. Epub 2007 Jun 28. Semin Cancer Biol. 2007. PMID: 17689098 Review.
-
[Importance of HLA-G in therapy of cancer].Therapie. 2008 Jul-Aug;63(4):327-32. doi: 10.2515/therapie:2008049. Epub 2008 Oct 22. Therapie. 2008. PMID: 18937912 Review. French.
-
Immune-refractory cancers and their little helpers--an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E?Semin Cancer Biol. 2007 Dec;17(6):459-68. doi: 10.1016/j.semcancer.2007.07.005. Epub 2007 Jul 31. Semin Cancer Biol. 2007. PMID: 17768067 Review.
-
Human leukocyte antigen-G and cancer immunoediting.Cancer Res. 2008 Feb 1;68(3):627-30. doi: 10.1158/0008-5472.CAN-07-2704. Cancer Res. 2008. PMID: 18245459 Review.
-
Human leukocyte antigen-G in cancer: are they clinically relevant?Cancer Lett. 2011 Dec 8;311(2):123-30. doi: 10.1016/j.canlet.2011.07.019. Epub 2011 Jul 22. Cancer Lett. 2011. PMID: 21843913 Review.
Cited by
-
Aberrant human leucocyte antigen-G expression and its clinical relevance in hepatocellular carcinoma.J Cell Mol Med. 2010 Aug;14(8):2162-71. doi: 10.1111/j.1582-4934.2009.00917.x. Epub 2010 Oct 3. J Cell Mol Med. 2010. PMID: 19799650 Free PMC article.
-
The use of anchored agonists of phagocytic receptors for cancer immunotherapy: B16-F10 murine melanoma model.PLoS One. 2014 Jan 13;9(1):e85222. doi: 10.1371/journal.pone.0085222. eCollection 2014. PLoS One. 2014. PMID: 24454822 Free PMC article.
-
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication.Immunol Rev. 2011 May;241(1):104-18. doi: 10.1111/j.1600-065X.2011.01007.x. Immunol Rev. 2011. PMID: 21488893 Free PMC article. Review.
-
HLA-G, cytokines, and cytokine receptors in the non-aggressive basal cell carcinoma microenvironment.Arch Dermatol Res. 2022 Apr;314(3):247-256. doi: 10.1007/s00403-021-02218-x. Epub 2021 Apr 3. Arch Dermatol Res. 2022. PMID: 33811555
-
Unfavourable clinical implications for HLA-G expression in acute myeloid leukaemia.J Cell Mol Med. 2008 Jun;12(3):889-98. doi: 10.1111/j.1582-4934.2008.00175.x. J Cell Mol Med. 2008. PMID: 18494931 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials